By Mill Chart
Last update: Dec 22, 2023
AMGEN INC (NASDAQ:AMGN) has caught the attention of dividend investors as a stock worth considering. NASDAQ:AMGN excels in profitability, solvency, and liquidity, all while providing a decent dividend. Let's delve into the details.
ChartMill assigns a Dividend Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing various dividend elements, such as yield, historical performance, dividend growth, and sustainability. NASDAQ:AMGN has been awarded a 7 for its dividend quality:
ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:AMGN, the assigned 5 for health provides valuable insights:
ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:AMGN, the assigned 8 is a significant indicator of profitability:
Our Best Dividend screener lists more Best Dividend stocks and is updated daily.
Check the latest full fundamental report of AMGN for a complete fundamental analysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
AMGEN INC
NASDAQ:AMGN (4/26/2024, 7:00:00 PM)
After market: 270.3 +0.32 (+0.12%)269.98
+0.6 (+0.22%)
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency...
These two pharma stocks have followed distinct paths of late. Which is the better investment?
This Vanguard growth fund is home to some of the world's most innovative companies.
Explore opportunities in the cable, restaurant and biotechnology sectors, revealing how dividend growth stocks are maximizing returns.
Though stocks that make the Dow 30 are often seen as solid investments, investors should consider these three blue chip stocks to sell.
When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.
Amgen's shares have come under pressure this year, making it a compelling bargain buy.
Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic...
Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now.